Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 210 participants.

Also called NCT06421870

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 210 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06421870
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06421870. Randomized; no masking; primary purpose treatment. Start 2024-03-01 (actual); primary completion 2025-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients
Condition
Chronic Kidney Diseases
Intervention (Drug)
Dapagliflozin 10mg Tab
Intervention (Drug)
Pentoxifylline 400 MG
Lead sponsor
Ain Shams University (class: other)

Record details

Record id
cardio:ct-nct06421870
Content hash
5c9301736c3fc8c6f768e24158e64f8781b1f5061ba47faaf25b8c9665562f60